All In Biotech

Drug Trial Radar · NCT07773246

Phase 1/2 Study of KRRO-121 in Healthy Volunteers and Patients With UCD

A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KRRO-121 in Healthy Volunteers and Patients With Urea Cycle Disorders

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Sep 28, 2026

Primary completion

Aug 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Korro Bio, Inc.Industry
Sponsor type
Industry
First posted
Aug 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Phase 1/2 Study of KRRO-121 is a randomized, placebo-controlled study in Healthy Volunteers (Phase 1 SAD and MAD) and Study Participants with Urea Cycle Disorders (Phase 2). The primary objective of the study is to evaluate the safety of KRRO-121.

Conditions

  • Urea Cycle Disorders, Inborn
  • Urea Cycle Disorders
  • Ornithine Transcarbamylase (OTC) Deficiency
  • Arginase 1 Deficiency
  • NAGS Deficiency
  • Carbamylphosphate Synthetase I
  • Ornithine Transporter Mitochondrial 1
  • Argininosuccinate Synthase
  • Argininosuccinate Lyase Deficiency
  • N-acetyl Glutamate - Synthetase
  • Citrin Deficiency

Interventions

  • KRRO-121Drug

    KRRO-121, subcutaneous injection

  • PlaceboDrug

    Placebo, subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose limiting toxicities (DLT) (Safety and Tolerability)Time frame: Day 1 through 14 days post-dose
  2. Frequency and severity of treatment-emergent adverse events (TEAEs; per Common Terminology Criteria for Adverse Events [CTCAE]) (Safety and Tolerability)Time frame: Day 1 through Day 50

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network Pty Ltd

    Melbourne, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.